Emboline Receives FDA 510(k) Clearance for Emboliner

San Jose, California, September 9, 2026

FDA Clearance Expands Embolic Protection Technology

The Emboliner Embolic Protection System is designed to provide embolic protection during TAVR by filtering debris released into the bloodstream during the procedure. TAVR involves replacing a diseased aortic valve using a catheter-based approach, and manipulation of the aortic valve and surrounding anatomy can dislodge calcific, thrombotic and tissue debris. These materials can migrate through the bloodstream and may reach the brain or other organs. The Emboliner system is intended to help address this procedural risk by providing full-body embolic protection during TAVR. The newly cleared system builds on Emboline’s technology for capturing embolic material while maintaining blood flow through the aortic arch. According to the company, the device is designed to protect the cerebral and systemic circulation during valve replacement procedures. The 510(k) clearance means the FDA has determined the device to be substantially equivalent to a legally marketed predicate device for its intended use. It is important to distinguish this regulatory pathway from pharmaceutical approval because a 510(k) clearance is specific to medical-device marketing authorization.

Emboliner Targets Debris During TAVR Procedures

TAVR has become an established treatment option for patients with aortic valve disease, including individuals who may be at elevated risk for complications associated with open-heart surgery. However, the procedure can generate embolic debris. Emboline’s technology is designed to address this issue by positioning a filter within the aortic arch to capture debris before it can travel downstream. The Emboliner system is intended to capture a broad range of embolic material, including particles that may be generated during valve implantation. By providing protection across the vessels supplying the brain and other organs, the system is designed around a whole-body embolic protection approach, rather than focusing solely on cerebral vessels. This distinction is an important aspect of the technology’s intended clinical application. Emboline has previously studied the Emboliner platform in clinical settings, including investigations examining the amount and characteristics of embolic debris captured during TAVR. The company’s broader development strategy is focused on reducing procedure-related embolic risk while supporting the continued expansion of minimally invasive structural heart interventions.

Regulatory Milestone Supports Commercial Expansion

The latest FDA clearance provides Emboline with an important regulatory milestone as the company continues efforts to expand access to embolic protection technology in the United States. The clearance also reinforces the company’s focus on developing devices intended to improve the safety profile of catheter-based cardiovascular procedures. The announcement is particularly relevant as TAVR continues to be used across an increasingly broad patient population. As procedural volumes grow, technologies designed to address complications associated with embolic debris could become increasingly important within the structural heart field. However, the FDA clearance itself should not be interpreted as evidence that the device eliminates the risk of stroke or other TAVR-related complications.For the medical-device industry, the clearance demonstrates continued regulatory progress in technologies designed to support safer transcatheter cardiovascular procedures. Emboline’s Emboliner system represents an example of how specialized embolic protection devices are being developed to address procedural risks associated with structural heart interventions. The FDA 510(k) milestone therefore strengthens Emboline’s position in the interventional cardiology and structural heart technology market while providing another regulatory step for a device focused on embolic protection during TAVR.

Source: Emboline press release